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Abstract. Alzheimer’s disease (AD) is a progressive neurodegenerative 
condition that results in severe cognitive and functional decline in sufferers and 
for which there are currently no effective treatments to halt or reverse disease 
progression. AD is the most common form of dementia and age is the major 
risk factor for this disease. With worldwide population structures changing as 
increasing number of individuals survive into old age, there is urgent need for 
novel disease modifying treatments for this condition, which has profound 
effects upon sufferers in addition to those around them. Some of us have 
previously developed a peptide inhibitor of Aβ1-42 aggregation (RI-OR2-TAT) 
that has been shown to reduce Aβ1-42 pathology in vivo in mouse models of AD. 
~1690 copies of RI-OR2-TAT have been covalently attached to nanoliposome 
carrier particles forming Peptide Inhibitor NanoParticles (PINPs), and this 
study investigated the effect of PINPs upon Aβ1-42 aggregation at the molecular 
level. Our results show that PINPs are able to reduce Aβ1-42 aggregation and do 
so by binding early (oligomers) and late (fibrillar) stage aggregates. These 
results highlight the ability of PINPs to disrupt the formation of multiple Aβ1-42 
aggregates capable of causing neurotoxicity and thus provide a strong case for 
PINPs to be carried forward into early stage clinical trials as a novel 
therapeutic option for the treatment of AD. 
1.  Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and is the leading cause of 
dementia [1]. The disease is listed as one of the most common causes of death in many countries, 
causing numerous symptoms such as impaired memory, cognitive decline, difficulty in 
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communication, and ultimately in the inability to perform activities of daily living. The major risk 
factor for AD is age, with the late-onset form (responsible for approximately 95% of cases) affecting 
individuals over the age of 65 [1]. Population structures continue to change as increasing numbers of 
people are surviving into old age and a result, the need to address the lack of treatments available for 
diseases of old age such as AD is clear. AD affects, on average, 1 in 9 individuals over the age of 65 
and this figure rises to 1 in 3 individuals over the age of 85 [2]. The characteristic pathological 
features of AD are the formation of extracellular senile plaques and intracellular neurofibrillary 
tangles. The senile plaques are formed by self-aggregation of the amyloid-β (Aβ) peptide, which is 
cleaved from a precursor protein – APP – by β- and γ- secretases, whilst the neurofibrillary tangles are 
formed from hyperphosphorylated Tau protein. Aggregation of the Aβ1-42 peptide primarily occurs via 
amino acid residues 16-22 which comprise the sequence KLVFFAE [3,4]. Aβ assembles into toxic 
aggregates of varying sizes, however it is thought that the most neurotoxic forms are aggregates 
consisting of a small number of peptides, referred to as oligomers [5]. A multitude of evidence exists 
to suggest that at least some of the neurodegeneration observed in AD is due to the Aβ peptide. 
Current therapies available to sufferers of AD are aimed at alleviating the symptoms of the disease 
rather than impacting upon disease progression. Although these treatments have been shown to reduce 
the rate of cognitive decline in AD sufferers, their lack of effect upon the underlying cause of the 
disease means that their beneficial effect is only temporary. In order to prevent the progression of AD, 
disease modifying therapies (DMTs) are required which address the underlying pathological 
mechanisms of the disease and thus prevent, or maybe even reverse, the effects of AD. As of yet, no 
DMTs have progressed past phase III trials and, therefore, there are none available for the treatment of 
AD. 
Previously, we have developed a brain-penetrating retro-inverso peptide inhibitor (RI-OR2-TAT, 
Ac-rGffvlkGrrrrqrrkkrGy-NH2) that blocks the in vitro formation and toxicity of the Aβ oligomers  
whilst also stimulating neurogenesis [6]. Previous studies have indicated that the aggregation 
inhibiting activity of this peptide is due to competitive binding between RI-OR2-TAT and Aβ1-42 
monomers for the KLVFF region of the Aβ1-42 peptide [4]. In this project RI-OR2-TAT has been 
attached to the surface of liposomes to attempt to produce a multivalent inhibitor of Aβ1-42 toxicity 
(termed Peptide Inhibitor NanoParticles – PINPs), and we have analyzed the interaction of the PINPs 
with Aβ1-42 at the molecular level by transmission electron microscopy (TEM). It is hoped that RI-
OR2-TAT will prove to be a successful DMT for AD, thus providing a more positive prognosis for the 
tens of millions of people suffering from this disease worldwide [7]. 
2.  Materials and Methods 
2.1.  PINPs 
PINPs were produced by Dr M Gregori and Dr M Masserini at the University of Milano-Bicocca, 
Milan, Italy. Liposomes consist of 1:1 cholesterol:sphingomyelin with 5% maleimide polyethylene 
glycol (PEG). RI-OR2-TAT is attached to the PEG via the maleimide group by ‘click-chemistry’ to 
form PINPs. PINPs were solubilized in either PBS or MilliQ water. 
2.2.  Transmission Electron Microscopy 
Samples were imaged using a JEOL JEM 1010 transmission electron microscope at an operating 
voltage of 80kV. Samples were placed on 300-mesh carbon/formvar coated copper grids (Agar 
Scientific, UK) and negatively stained with 2% (w/v) phosphotungstic acid (PTA) pH 7.4. 
2.2.1.  Immunolabeling 
Briefly, 4μl of sample was added to grids for 1 minute, blotted and grids were blocked in 1:10 Goat 
serum:PBS+. Samples were then incubated with primary antibody (6E10, BioLegend) at room 
temperature for 1h, washed with PBS+, incubated with secondary antibody (G777, Sigma-Aldrich) for 
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1h, washed in PBS+ and then a further wash in MilliQ water. Grids were then negatively stained by 
addition 4μl of PTA stain for 1 minute. 
3.  Results 
The purpose of this study was to investigate any interactions between PINPs and Aβ1-42 using TEM. 




Aβ1-42 samples incubated at 37oC for 48 hours in the absence of PINPs revealed numerous large masses 
of aggregation, illustrating the tendency of Aβ1-42 to self-aggregate into the multimeric aggregates 
associated with toxicity in AD (Figure 1A). Interestingly, PINPs + Aβ1-42 coincubation resulted in an 
altered appearance of PINPs (1B-Before, 1C-After), with PINPs appearing much ‘rougher’ than when 
observed in the absence of Aβ1-42. A proposed explanation for this finding was the binding of small 
oligomers to the PINP surface. The number of Aβ1-42 aggregates observed in the absence of PINPs was 
increased in comparison to the sample in which PINPs were present. Upon analysis, the Aβ1-42 + PINPs 
sample clearly showed PINPs binding to Aβ1-42 fibrils of various lengths, with binding observed along 
the length of the fibril as well as to fibril termini (Figure 1D).  
3.2.  Immunogold labelling of PINPs to evaluate their ability to bind Aβ1-42 oligomers.  
Figure 2– Immunogold labelling to detect PINP bound Aβ1-42 oligomers. (A) Immunolabeling of Aβ1-42 




Figure 1 shows the effect of PINPs upon the aggregation of Aβ1-42 following 48-hour incubation at 37oC. 
(A) Aβ1-42 aggregates in absence of PINPs. (B) PINPs alone. Altered appearance of PINPs (C) and binding 
of PINPs to Aβ1-42 fibrils (D) following co-incubation. Scale bars = (A) = 200nm (B,C,D) =100nm. 
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To test the hypothesis that the altered appearance of PINPs in the presence of Aβ1-42 was due to 
binding of Aβ1-42 oligomers, immunolabeling was performed to detect any Aβ1-42 bound to the PINP 
surface. Results (Figure 2A) showed positive labelling (black dots) on the PINP surface indicating the 
presence of Aβ1-42 oligomers. Figure 2B shows that in the absence of the primary antibody, no 
immunolabeling is observed, illustrating that the secondary antibody only binds where the primary 
antibody is present, showing the specific labelling only where Aβ1-42 is present. Therefore the positive 
labelling on the PINP surface strongly indicates the presence of Aβ1-42.   
4. Discussion
This study investigated the interactions between PINPs and Aβ1-42 at the molecular level in an attempt
to evaluate the potential for PINPs to be carried forward as a novel treatment for AD.
Our results indicate that PINPs are able to suppress fibril formation and elongation as co-incubation 
of Aβ1-42 with PINPs resulted in much fewer dense Aβ1-42 aggregations than was observed with Aβ1-42
alone. Our results show that PINPs are able to bind directly Aβ1-42 fibrils, both along the length of the 
fibril and to fibril termini. These results suggest that binding of PINPs is able to inhibit further fibril 
elongation, providing a visual explanation for the termination of fibril elongation reported during 
analysis of RI-OR2 [4]. Whilst evaluating the ability of PINPs to interact with Aβ1-42, a change in 
PINP morphology was observed, which we hypothesized was due to the binding of Aβ1-42 oligomers. 
Binding of Aβ1-42 to the PINP surface was investigated and confirmed using an immunolabeling 
approach where 10nm gold conjugated antibodies were used to signal positive labeling, demonstrating 
the ability of PINPs to bind to early (oligomers) and late stage (fibrils) Aβ1-42 aggregates. Thus our 
results confirm that the peptide has retained the ability to interact with early and late stage aggregates 
despite attachment to the nanoliposomal carrier particle [4]. 
This study demonstrates that attachment of RI-OR2-TAT to nanoliposome carrier particles 
preserves the ability of the peptide to bind oligomers and mature fibrils, reducing total levels of Aβ1-42
aggregation and appearing to inhibit fibril elongation. PINPs were developed as a potential DMT for 
the treatment of AD. By attaching ~1690 RI-OR2-TAT peptides to the liposome surface, PINPs are 
able to function as a multivalent inhibitor of Aβ1-42 aggregation, with potential for use in the treatment 
of AD. We believe that these results demonstrate the strong potential that PINPs possess to be carried 
forward for further investigation, including early stage clinical trials in order to evaluate their safety 
and potential therapeutic efficacy in human subjects. 
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